Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Adjuvanted HBsAg Vaccines
NCT00508833Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2000
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Hepatitis B vaccine in hepatitis B (HBV), sponsored by GSK. Primary endpoint: Intensity of the CTL response at Week 6. Started Mar 2000; status: completed.
02
Drugs
Hepatitis B vaccine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00508833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00508833.